Filing summary
Entity and period: The supplied filing is Synta Pharmaceuticals Corp.’s Form 10-K for the fiscal year ended December 31, 2015, filed March 15, 2016. It does not appear to be a filing by Madrigal Pharmaceuticals, Inc.; the figures below summarize the filing provided.
Business context and reporting period
Synta was a clinical-stage oncology drug developer with no approved products or product revenue. Its lead clinical candidate was ganetespib, and its early-stage program included HDC candidate STA-12-8666. The filing reports full-year 2015 results and unaudited quarterly data, including fourth-quarter 2015.
Financial performance and position
| Metric | FY 2015 | FY 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $54.2 million | $68.2 million |
| General and administrative expense | $13.4 million | $15.7 million |
| Operating loss | $67.6 million | $84.0 million |
| Net loss | $68.7 million | $86.2 million |
| Loss per share, basic and diluted | $0.53 | $0.87 |
| Cash used in operating activities | $71.4 million | $78.9 million |
Fourth-quarter 2015 revenue was zero and net loss was $10.5 million, versus a $20.4 million net loss in fourth-quarter 2014. The company recorded a $2.9 million reduction in accrued contract research costs in Q4 2015, principally related to terminating GALAXY-2.
At December 31, 2015, cash, cash equivalents and marketable securities were $66.6 million, down from $97.7 million a year earlier; working capital was $50.0 million. Total assets were $68.2 million and stockholders’ equity was $50.4 million. Current term loans were $4.6 million, with no long-term term loans reported; scheduled GECC and Oxford loan obligations, including interest and an exit fee, totaled $5.5 million and were due in 2016. The company had an accumulated deficit of $706.2 million.
No meaningful operating margin is presented because the company had no revenue. The filing does not provide a product-based profitability measure.
Material changes versus the prior period
- Annual net loss narrowed by $17.5 million, while R&D expense declined 21%, mainly as ganetespib trial activity wound down.
- Cash and marketable securities fell $31.1 million despite $49.6 million of net proceeds from equity offerings and at-the-market sales during 2015.
- Weighted-average shares outstanding rose to 128.6 million from 98.5 million, reflecting substantial equity issuance.
- Operating cash use improved by $7.5 million year over year. Net financing cash inflow was $40.4 million, including equity proceeds and $9.2 million of loan principal repayments.
Outlook, risks and unusual items
- In October 2015, Synta terminated the Phase 3 GALAXY-2 ganetespib trial for futility: the independent monitoring committee concluded the treatment was unlikely to significantly improve overall survival versus docetaxel alone.
- In November 2015, the company reduced its workforce by 45 positions to 33; in February 2016, it committed to a further reduction of 23 positions, leaving 10 employees, and discontinued a substantial portion of R&D. The February restructuring was expected to cost about $1.5 million.
- Synta paused plans to file an IND for STA-12-8666. It intended to support the investigator-sponsored GANNET53 ovarian cancer and SARC 023 sarcoma trials, while winding down most other ganetespib studies.
- Management estimated that year-end cash resources, together with lower spending after the trial termination and restructurings, would fund operations for at least 12 months. This estimate assumed no new partnership funding, equity financing, or further ATM sales; spending plans remained subject to available resources.
- The company was evaluating alternatives including a sale, business combination, collaboration or partnership, cash distribution, or liquidation. No transaction was assured. Elesclomol was transferred under a January 2016 asset purchase agreement in exchange for a minority interest, board representation, potential milestone payments and royalties.
- NASDAQ had notified Synta that its share price failed the $1.00 minimum bid requirement; the stated deadline to regain compliance was May 31, 2016. The filing reported a March 10, 2016 closing bid of $0.23.
- Material risks include continued losses and cash depletion, uncertainty of strategic alternatives, limited remaining development programs, trial and product-liability obligations, loan covenants and repayment, potential dilution, and possible delisting. GECC debt was secured by substantially all assets, with a springing IP lien under specified covenant conditions.
- Auditor Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. The company reported no material legal proceedings.
Important facts for investors to verify
- Confirm the issuer: the source is Synta Pharmaceuticals Corp., not Madrigal Pharmaceuticals, Inc.
- Review current cash, actual burn and obligations after the 2016 restructuring against management’s 12-month runway estimate.
- Check the status and outcome of the strategic-alternatives process, including any transaction or cash distribution.
- Verify NASDAQ listing status and any subsequent share issuances, dilution, or ATM activity.
- Confirm the status, costs and obligations of the remaining ovarian cancer and sarcoma trials, and the development terms for elesclomol and the licensed CRACM program.